Advertisement
Zarxio
Specialty Drug

Filgrastim-Sndz

FILGRASTIM, G-CSF (fil GRA stim) is a granulocyte colony-stimulating factor that stimulates the growth of neutrophils, a type of white blood cell (WBC) important in the body's fight against infection. It is used to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow, to stimulate blood cell production for removal of WBCs from the body prior to a bone marrow transplantation, to reduce the incidence of fever and infection in patients who have severe chronic neutropenia, and to improve survival outcomes following high-dose radiation exposure that is toxic to the bone marrow. Compare leukocyte growth factors.
Advertisement

Zarxio Latest News

Get the latest updates on this drug from the GoodRx medical team

2015 In Review: The Good(Rx) and Bad

Elizabeth Davis - December 29, 2015

2015 was another tough year for American’s health care budgets. Insurance premiums increased, coverage was dropped for a number of important drugs, and overall we’re spending more for our health care.

Don’t break out the antidepressants yet—it’s not all bad news. A number of important drugs went generic, which will generally mean huge savings and lower costs. Plus, a large number of drugs actually decreased in price. See More

Neupogen Biosimilar Med Zarxio Now in Pharmacies!

The GoodRx Pharmacist - October 06, 2015

The first FDA approved biosimilar for distribution in the United States is now available!

Zarxio is an alternative to Neupogen (its “reference biologic”) and will be offered at a reduced cost.

Zarxio is considered a specialty medication but will be available for open distribution. Open distribution means that the medication can be dispensed by any licensed pharmacy—and you won’t need to order through a specialty pharmacy. See More

Neupogen Biosimilar Update: Zarxio Now FDA Approved

The GoodRx Pharmacist - March 17, 2015

On March 6, 2015, the FDA approved the first biosimilar for distribution in the United States. This is a huge approval, and an accomplishment for the pharmaceutical company, Sandoz, and their biosimilar, Zarxio (filgrastim-sndz).

This is such important news because biosimilars like Zarxio will offer a reduced cost alternative therapy to their expensive biologic counterparts where there have been previously been no lower-cost options. See More

GoodRx is not sponsored by or affiliated with any of the pharmacies identified in its price comparisons. All trademarks, brands, logos and copyright images are property of their respective owners and rights holders and are used solely to represent the products of these rights holders. This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data or other information. Please seek medical advice before starting, changing or terminating any medical treatment.